Form 4: Prime Medicine Executive Granted Stock Options

Carman Alenson, SVP, Finance and Chief Accounting Officer of Prime Medicine, Inc., was granted stock options for 90,500 shares on February 27, 2025.

Summary

• Carman Alenson, a Senior Vice President at Prime Medicine, Inc., received stock options to purchase 90,500 shares of common stock.
• The options were granted on February 27, 2025, with an exercise price of $2.42 per share.
• The options vest monthly over a four-year period, starting on February 27, 2025, contingent upon continued service.
• The options expire on February 27, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral to slightly positive event.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Prime Medicine.
• Companies such as CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also utilize stock options as part of their executive compensation strategy.
• The vesting schedule of 1/48th monthly is a typical vesting schedule for stock options.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the executive's performance leads to company growth.
• The grant incentivizes the executive to remain with the company, providing stability.

Key Dates